Literature DB >> 10501160

Potential of DNA-mediated vaccination for equine herpesvirus 1.

K M Ruitenberg1, C Walker, J E Wellington, D N Love, J M Whalley.   

Abstract

The potential of DNA-mediated immunisation to protect against equine herpesvirus 1 (EHV-1) disease was assessed in a murine model of EHV-1 respiratory infection. Intramuscular injection with DNA encoding the EHV-1 envelope glycoprotein D (gD) in a mammalian expression vector induced a specific antibody response detectable by two weeks and maintained through 23 weeks post injection. Immune responses were proportional to the dose of DNA and a second injection markedly enhanced the antibody response. EHV-1 gD DNA-injected mice developed neutralising antibodies, and a predominance of IgG2a antibodies after the DNA injection was consistent with the generation of a type 1 helper T-cell (Th1) response. Following intranasal challenge with EHV-1, mice immunised with 50 microg of EHV-1 gD DNA were able to clear virus more rapidly from lung tissue and showed reduced lung pathology in comparison with control mice. The data indicate that DNA-mediated immunisation may be a useful strategy for vaccination against EHV-1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501160     DOI: 10.1016/s0378-1135(99)00059-0

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  3 in total

1.  Pseudorabies virus glycoprotein gD contains a functional endocytosis motif that acts in concert with an endocytosis motif in gB to drive internalization of antibody-antigen complexes from the surface of infected monocytes.

Authors:  Jolanta Ficinska; Geert Van Minnebruggen; Hans J Nauwynck; Krystyna Bienkowska-Szewczyk; Herman W Favoreel
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

2.  Isolation and partial characterization of equine herpesvirus type 1 in Czechia.

Authors:  D Molinková; V Celer; P Jahn
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

3.  Effective treatment of respiratory alphaherpesvirus infection using RNA interference.

Authors:  Amy Fulton; Sarah T Peters; Gillian A Perkins; Keith W Jarosinski; Armando Damiani; Margaret Brosnahan; Elizabeth L Buckles; Nikolaus Osterrieder; Gerlinde R Van de Walle
Journal:  PLoS One       Date:  2009-01-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.